Booth 3653
Daejeon, Korea, Republic of
We are targeting the drugs for fibrotic and auto-immune diseases with high efficacy and safety. As is well-known, fibrotic disease such and liver cirrhosis, idiopathic pulmonary disease are serious diseases that cause numerous patients and deaths, but effective drugs have not yet been developed. Several leading companies have been developing treatments for these diseases, but it has been difficult to develop that can overcome side effects as well as efficient efficacy.

There are also many drugs on the market for hypertrophic scars. However, there is still strong demand for treatment with high therapeutic effects and less side effects. Our preclinical investigation discovered an effective anti-fibrotic therapy – chiral enantiomers of the drugs that has been used as orphan drugs which are deemed safe through history of long-term prescription of their racemic drugs. The candidates would not come across hurdles of toxicity and side effects onto clinical trials which has been a big challenge to overcome.

The candidates exert anti-inflammatory and anti-fibrotic effect via elevating adenosine levels; adenosine suppresses immune and fibrotic responses via activating adenosine A2A and A2B receptors.
We are also developing a novel diagnostic kit for vascular disease, which works by measuring biomarkers expressed during early-stage vascular abnormality. Our technology helps patients in need through early detection in contrast to current methods of ultrasound or angiogram used at a severe, late-stage.

CelionBioMed is a company focused on early-stage technology development. We look forward to finding companies that can cooperate with us to develop and commercialize our technology. We are searching for companies interested in our technology for commercialization.
***Company objectives-
Our promising drug candidates are targeted to:
• Liver cirrhosis,
• Idiopathic pulmonary fibrosis,
• Hypertropic scar and keloid,
• Vascular disease diagnosis